EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 3.0

Bronchial Artery Chemoembolization (BACE) Combined with PD-1 Blockade Versus Chemotherapy Combined with PD-1 Blockade for Non-Small Cell Lung Cancer in Older Adults

Jing Xiang, Jianfei Tu, Weiwei Gong, Panhang Chen, Yonghui Wang, Weiwen Li, Jieming Zhong, Jiansong Ji iD, Jianhui Huang iD

Clinical Interventions in Aging · 2026

DOI: 10.2147/cia.s623443 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Interventions in Aging, 2026. Verfasst von Jing Xiang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology Center, Lishui Central Hospital, Lishui, Zhejiang, 323000, People's Republic of China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Chemoembolization, Therapeutic, Lung Neoplasms, Bronchial Arteries. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Systemic immunochemotherapy is the standard of care in patients with advanced non-small cell lung cancer (NSCLC) without druggable driving mutations, yet many older patients cannot tolerate systemic chemotherapy. Bronchial arterial chemoembolization (BACE) represents an alternative to systemic chemotherapy for this population.

Methods

This retrospective single-center study included consecutive patients with stage IIIC-IV NSCLC over 65 years old who underwent BACE or systemic chemotherapy, plus a PD-1 inhibitor, in our hospital from August 2019 to October 2024. The objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), overall survival (OS), and adverse events (AEs) were compared between the two groups.

Results

The final analysis included 81 patients: 39 and 42 in the chemotherapy and BACE groups, respectively. In comparison to the chemotherapy group, the BACE group had older age (median age: 78 vs 71 years) and poorer Eastern Cooperative Oncology Group Performance Status (ECOG PS≥2: 47.6% vs 2.6%). The ORR was 73.8% in the BACE group vs 64.1% in the chemotherapy group. The median PFS was 5.4 months in the BACE group vs 5.2 months in the chemotherapy group (P=0.841). The median OS was 10.3 months in the BACE group vs 8.7 months in the chemotherapy group (P=0.449). Neither PFS nor OS differed significantly between the 2 groups in either Cox proportional hazards regression or inverse probability of treatment weighting analyses. The BACE group had lower rate of myelosuppression (28.6% vs 74.4%) but higher rate of dyspnea (16.7% vs 0%). No treatment-related serious AEs, eg, spinal artery injury due to ectopic embolism or venous thrombosis of the lower limb, were reported in the BACE group.

Conclusion

In older patients with stage IIIC-IV NSCLC, BACE combined with PD-1 inhibitor showed no statistically inferior response or survival versus chemoimmunotherapy. These exploratory results require validation in large prospective cohorts.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungChemoembolization, TherapeuticLung NeoplasmsBronchial ArteriesImmune Checkpoint InhibitorsHumansAgedFemaleRetrospective StudiesMaleAged, 80 and overProgrammed Cell Death 1 ReceptorCombined Modality Therapy

Stichwörter der Autor:innen

bronchial arterial chemoembolizationefficacyimmunotherapynon-small lung cancerolder adults

Substanzen

Programmed Cell Death 1 ReceptorImmune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Oncology Center, Lishui Central Hospital, Lishui, Zhejiang, 323000, People's Republic of China.
  • Department of Chronic Disease Prevention and Control, Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, Zhejiang, 310051, People's Republic of China.
  • Department of Oncology Center, the Fifth Affiliated Hospital of Wenzhou Medical University, Lishui, Zhejiang, 323000, People's Republic of China.
  • Department of Interventional Radiology, The Fifth Affiliated Hospital of Wenzhou Medical University, Lishui, Zhejiang, 323000, People's Republic of China.

ORCID-Profile: Jiansong Ji, Jianhui Huang

Zitieren

APA

Xiang, J., Tu, J., Gong, W., Chen, P., Wang, Y., Li, W., Zhong, J., Ji, J., & Huang, J. (2026). Bronchial Artery Chemoembolization (BACE) Combined with PD-1 Blockade Versus Chemotherapy Combined with PD-1 Blockade for Non-Small Cell Lung Cancer in Older Adults. Clinical Interventions in Aging. https://doi.org/10.2147/cia.s623443

Vancouver

Xiang J, Tu J, Gong W, Chen P, Wang Y, Li W, et al. Bronchial Artery Chemoembolization (BACE) Combined with PD-1 Blockade Versus Chemotherapy Combined with PD-1 Blockade for Non-Small Cell Lung Cancer in Older Adults. Clinical Interventions in Aging. 2026. doi:10.2147/cia.s623443

BibTeX
@article{Xiang2026,
  author = {Xiang, Jing and Tu, Jianfei and Gong, Weiwei and Chen, Panhang and Wang, Yonghui and Li, Weiwen and Zhong, Jieming and Ji, Jiansong and Huang, Jianhui},
  title = {Bronchial Artery Chemoembolization (BACE) Combined with PD-1 Blockade Versus Chemotherapy Combined with PD-1 Blockade for Non-Small Cell Lung Cancer in Older Adults},
  journal = {Clinical Interventions in Aging},
  year = {2026},
  doi = {10.2147/cia.s623443}
}
Kostenlos starten →